Bruker Dirección
Dirección controles de criterios 4/4
El CEO de Bruker es Frank Laukien , nombrado en Feb 1991, tiene una permanencia de 33.75 años. compensación anual total es $5.86M, compuesta por 15.8% salario y 84.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 26.62% de las acciones de la empresa, por valor de $2.30B. La antigüedad media del equipo directivo y de la junta directiva es de 10.6 años y 9.3 años, respectivamente.
Información clave
Frank Laukien
Chief Executive Officer (CEO)
US$5.9m
Compensación total
| Porcentaje del salario del CEO | 15.8% |
| Permanencia del CEO | 33.8yrs |
| Participación del CEO | 26.6% |
| Permanencia media de la dirección | 10.6yrs |
| Promedio de permanencia en la Junta Directiva | 9.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Bruker's (NASDAQ:BRKR) Anemic Earnings Might Be Worse Than You Think
Nov 14
Bruker: Still Challenged, Certainly Margins
Nov 02Earnings Tell The Story For Bruker Corporation (NASDAQ:BRKR)
Oct 25We Think Bruker (NASDAQ:BRKR) Is Taking Some Risk With Its Debt
Sep 10Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In
Aug 22Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 22Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price
Jun 09Bruker: A Confusing Acquisition Spree
May 31Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations
May 09Bruker Corporation: An Aggressive Acquisition Strategy
Apr 24Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research
Apr 11Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Jan 22There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price
Jan 08Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?
Dec 26Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?
Nov 06Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Oct 23Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors
Sep 25Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?
Aug 09Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 27Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet
Jul 11Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$305m |
| Jun 30 2024 | n/a | n/a | US$352m |
| Mar 31 2024 | n/a | n/a | US$402m |
| Dec 31 2023 | US$6m | US$926k | US$427m |
| Sep 30 2023 | n/a | n/a | US$319m |
| Jun 30 2023 | n/a | n/a | US$319m |
| Mar 31 2023 | n/a | n/a | US$312m |
| Dec 31 2022 | US$5m | US$873k | US$297m |
| Sep 30 2022 | n/a | n/a | US$275m |
| Jun 30 2022 | n/a | n/a | US$274m |
| Mar 31 2022 | n/a | n/a | US$282m |
| Dec 31 2021 | US$6m | US$812k | US$277m |
| Sep 30 2021 | n/a | n/a | US$270m |
| Jun 30 2021 | n/a | n/a | US$238m |
| Mar 31 2021 | n/a | n/a | US$204m |
| Dec 31 2020 | US$4m | US$689k | US$158m |
| Sep 30 2020 | n/a | n/a | US$158m |
| Jun 30 2020 | n/a | n/a | US$165m |
| Mar 31 2020 | n/a | n/a | US$177m |
| Dec 31 2019 | US$5m | US$753k | US$197m |
| Sep 30 2019 | n/a | n/a | US$207m |
| Jun 30 2019 | n/a | n/a | US$189m |
| Mar 31 2019 | n/a | n/a | US$184m |
| Dec 31 2018 | US$4m | US$731k | US$180m |
| Sep 30 2018 | n/a | n/a | US$98m |
| Jun 30 2018 | n/a | n/a | US$92m |
| Mar 31 2018 | n/a | n/a | US$84m |
| Dec 31 2017 | US$5m | US$704k | US$79m |
Compensación vs. Mercado: La compensación total ($USD5.86M) de Frank está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD7.74M).
Compensación vs. Ingresos: La compensación de Frank ha sido consistente con los resultados de la empresa en el último año.
CEO
Frank Laukien (64 yo)
33.8yrs
Permanencia
US$5,858,761
Compensación
Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 33.8yrs | US$5.86m | 26.62% $ 2.3b | |
| Executive VP & CFO | 6.7yrs | US$2.20m | 0.033% $ 2.8m | |
| Corporate Executive VP and President of Bruker Nano Group & Corporate | 9.3yrs | US$2.73m | 0.050% $ 4.4m | |
| President of Bruker CALID Group & Bruker Daltonics Division | 11.8yrs | US$1.47m | 0.081% $ 7.0m | |
| President of Bruker BioSpin Group | 6.5yrs | US$1.35m | 0.016% $ 1.4m | |
| Senior Director of Investor Relations & Corporate Development | no data | sin datos | sin datos | |
| General Counsel & Secretary | no data | sin datos | sin datos | |
| President and CEO of Bruker Energy & Supercon Technologies | 16.6yrs | US$967.91k | 0.0090% $ 776.9k |
10.6yrs
Permanencia media
62yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BRKR es experimentado (10.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 33.8yrs | US$5.86m | 26.62% $ 2.3b | |
| Independent Director | 9.3yrs | US$241.01k | 0.014% $ 1.2m | |
| Independent Director | 9yrs | US$224.01k | 0.019% $ 1.6m | |
| Independent Director | 17.5yrs | US$227.32k | 0.047% $ 4.1m | |
| Independent Lead Director | 24.8yrs | US$231.01k | 0.022% $ 1.9m | |
| Independent Director | 7.5yrs | US$224.01k | 0.013% $ 1.1m | |
| Independent Director | 9.3yrs | US$219.01k | 0.014% $ 1.2m | |
| Independent Director | 4.2yrs | US$219.65k | 0.0050% $ 436.9k | |
| Independent Director | 8.5yrs | US$216.83k | 0.0076% $ 661.0k |
9.3yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de BRKR se considera experimentada (9.3 años de antigüedad promedio).